Single-Dose IV Oritavancin Diphosphate

DRUG4 trials

Sponsors

Melinta Therapeutics, Inc.

Conditions

AbscessCellulitisHealthySystemic InflammationWound Infection

Phase 1

A Study to Assess the Cardiac Safety of Oritavancin in Healthy Participants

CompletedNCT01762839

Melinta Therapeutics, Inc.Healthy

Start: 2012-12-27End: 2013-02-11Updated: 2024-02-01

Open Label Study Evaluating the Effects of a Single Oritavancin Infusion on Cytochrome P450 in Healthy Volunteers

CompletedNCT01784536

Melinta Therapeutics, Inc.Healthy

Start: 2013-01-31End: 2013-03-31Updated: 2023-12-19

Phase 3

Oritavancin Versus IV Vancomycin for the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infection

CompletedNCT01252732

Melinta Therapeutics, Inc.Abscess, Cellulitis, Systemic Inflammation +1

Start: 2010-12-31End: 2013-06-30Updated: 2021-05-05

Oritavancin Versus IV Vancomycin for the Treatment of Participants With Acute Bacterial Skin and Skin Structure Infection (SOLO I)

CompletedNCT01252719

Melinta Therapeutics, Inc.Abscess, Cellulitis, Systemic Inflammation +1

Start: 2010-12-31End: 2012-11-30Updated: 2022-08-01

Related Papers

Single Intravenous Dose of Oritavancin for Treatment of Acute Skin and Skin Structure Infections Caused by Gram-Positive Bacteria: Summary of Safety Analysis from the Phase 3 SOLO Studies

Antimicrobial Agents and Chemotherapy2018-01-1823 citations

Single-Dose Oritavancin Treatment of Acute Bacterial Skin and Skin Structure Infections: SOLO Trial Efficacy by Eron Severity and Management Setting

Infectious Diseases and Therapy2016-07-0117 citations

Single-Dose Oritavancin Versus 7–10 Days of Vancomycin in the Treatment of Gram-Positive Acute Bacterial Skin and Skin Structure Infections: The SOLO II Noninferiority Study

Clinical Infectious Diseases2014-10-06215 citations

Single-Dose Oritavancin in the Treatment of Acute Bacterial Skin Infections

New England Journal of Medicine2014-06-04298 citations